Skip to main navigation

Investor Relations

April 14, 2021

Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis

March 31, 2021

Abivax reports 2020 financial results and operations update

March 05, 2021

Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy

March 03, 2021

Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal “Gastroenterology"

March 01, 2021

Abivax appoints Dr Sophie Biguenet as Chief Medical Officer